Haemonetics (HAE) Misses Q4 EPS by 21c, Revenues Beat; Offers FY22 EPS Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HAE Hot Sheet
Price: $127.42 +5.94%
Revenue Growth %: +5.6%
Financial Fact:
Research, development and engineering: 8.34M
Today's EPS Names:
COHR, ATS, SICP, More
Revenue Growth %: +5.6%
Financial Fact:
Research, development and engineering: 8.34M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Haemonetics (NYSE: HAE) reported Q4 EPS of $0.46, $0.21 worse than the analyst estimate of $0.67. Revenue for the quarter came in at $225 million versus the consensus estimate of $222.98 million.
GUIDANCE:
Haemonetics sees FY2022 EPS of $2.60-$3.00, versus the consensus of $2.56.
For earnings history and earnings-related data on Haemonetics (HAE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phibro Animal Health (PAHC) Tops Q1 EPS by 2c; Offers Guidance
- Ingevity (NGVT) Tops Q3 EPS by 7c, Beats on Revenue; Offers FY26 EPS Guidance
- UWM Holdings Corporation (UWMC) Reports Q3 results
Create E-mail Alert Related Categories
Corporate News, Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
